Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study

Abstract Background To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled co...

Full description

Bibliographic Details
Main Authors: Jean Bousquet, Neil Barnes, Michael Gibbs, Nadeem Gul, Susan A Tomkins, Xin Zhou, Young-Joo Cho, Hae-Sim Park, William Busse, Nanshan Zhong
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Pulmonary Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12890-017-0410-x
_version_ 1819092571360591872
author Jean Bousquet
Neil Barnes
Michael Gibbs
Nadeem Gul
Susan A Tomkins
Xin Zhou
Young-Joo Cho
Hae-Sim Park
William Busse
Nanshan Zhong
author_facet Jean Bousquet
Neil Barnes
Michael Gibbs
Nadeem Gul
Susan A Tomkins
Xin Zhou
Young-Joo Cho
Hae-Sim Park
William Busse
Nanshan Zhong
author_sort Jean Bousquet
collection DOAJ
description Abstract Background To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled corticosteroid (ICS)-naïve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and randomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma or maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was the proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total Control and adverse events. Asian and non-Asian patients were analysed separately. Results In Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus 74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three strata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly and with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during PhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns were identified. Conclusions A greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally Controlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian patients in S1 achieved Well-Controlled asthma in both treatment groups.
first_indexed 2024-12-21T22:57:44Z
format Article
id doaj.art-1b57930019464b279e8c59e559ad5f2e
institution Directory Open Access Journal
issn 1471-2466
language English
last_indexed 2024-12-21T22:57:44Z
publishDate 2017-04-01
publisher BMC
record_format Article
series BMC Pulmonary Medicine
spelling doaj.art-1b57930019464b279e8c59e559ad5f2e2022-12-21T18:47:23ZengBMCBMC Pulmonary Medicine1471-24662017-04-0117111210.1186/s12890-017-0410-xAsthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL studyJean Bousquet0Neil Barnes1Michael Gibbs2Nadeem Gul3Susan A Tomkins4Xin Zhou5Young-Joo Cho6Hae-Sim Park7William Busse8Nanshan Zhong9Fondation MACVIA-LR, Contre les Maladies Chroniques pour un Vieillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, University of MontpellierGlobal Respiratory Franchise, GSK HouseGlobal Respiratory Franchise, GSK HouseQuantitative Science, Clinical Statistics, GSKQuantitative Science, Clinical Statistics, GSKShanghai First People’s HospitalEwha Womans University, School of MedicineAjou University Medical CenterUniversity of Wisconsin, School of Medicine and Public HealthState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical UniversityAbstract Background To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in Asian patients. Methods A post hoc analysis of the GOAL study in which patients were stratified by prior-medication use into inhaled corticosteroid (ICS)-naïve (Stratum [S] 1), low-dose ICS (S2), and medium-dose ICS (S3), and randomised to receive FP/SAL or FP. Doses were stepped-up every 12 weeks until Totally Controlled asthma or maximum dose was reached (PhI) and then maintained until study end (PhII). The primary endpoint was the proportion of patients achieving Well-Controlled asthma during PhI. Additional endpoints included Total Control and adverse events. Asian and non-Asian patients were analysed separately. Results In Asian patients in PhI, 74% (n = 87/118) in S1 achieved Well-Controlled asthma with FP/SAL versus 74% (n = 89/121) with FP alone (p = 0.839); corresponding values were 76% (n = 81/107) versus 60% (n = 62/104; p = 0.005) in S2, and 58% (n = 59/102) versus 43% (n = 41/95; p = 0.015) in S3. More patients in all three strata achieved Totally Controlled asthma with FP/SAL versus FP alone. Control was achieved more rapidly and with lower ICS doses with FP/SAL versus FP. A high proportion of patients who achieved control during PhI maintained control during PhII. Similar trends were found in non-Asian patients. No new safety concerns were identified. Conclusions A greater proportion of Asian patients (S2 and S3, for Well-Controlled; all strata, for Totally Controlled) achieved guideline-defined asthma control with FP/SAL versus FP alone. High proportions of Asian patients in S1 achieved Well-Controlled asthma in both treatment groups.http://link.springer.com/article/10.1186/s12890-017-0410-xAsian patientsAsthmaAsthma controlAsthma treatmentFluticasone propionate/salmeterolICS/LABA treatment
spellingShingle Jean Bousquet
Neil Barnes
Michael Gibbs
Nadeem Gul
Susan A Tomkins
Xin Zhou
Young-Joo Cho
Hae-Sim Park
William Busse
Nanshan Zhong
Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
BMC Pulmonary Medicine
Asian patients
Asthma
Asthma control
Asthma treatment
Fluticasone propionate/salmeterol
ICS/LABA treatment
title Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
title_full Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
title_fullStr Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
title_full_unstemmed Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
title_short Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
title_sort asthma control using fluticasone propionate salmeterol in asian and non asian populations a post hoc analysis of the goal study
topic Asian patients
Asthma
Asthma control
Asthma treatment
Fluticasone propionate/salmeterol
ICS/LABA treatment
url http://link.springer.com/article/10.1186/s12890-017-0410-x
work_keys_str_mv AT jeanbousquet asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT neilbarnes asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT michaelgibbs asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT nadeemgul asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT susanatomkins asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT xinzhou asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT youngjoocho asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT haesimpark asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT williambusse asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy
AT nanshanzhong asthmacontrolusingfluticasonepropionatesalmeterolinasianandnonasianpopulationsaposthocanalysisofthegoalstudy